[{"id":"bbe41355-ce82-4603-9e1f-23b747152758","acronym":"","url":"https://clinicaltrials.gov/study/NCT07186842","created_at":"2025-09-27T08:38:32.247Z","updated_at":"2025-09-27T08:38:32.247Z","phase":"Phase 1/2","brief_title":"A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9","source_id_and_acronym":"NCT07186842","lead_sponsor":"BioNTech SE","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 05/01/2030","primary_completion_date":" 05/01/2030","study_txt":" Completion: 05/01/2030","study_completion_date":" 05/01/2030","last_update_posted":"2025-09-22"},{"id":"6a3b2e5b-0a7d-4873-a9a6-c4dee0b91e9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT07122466","created_at":"2025-08-16T14:02:18.822Z","updated_at":"2025-08-16T14:02:18.822Z","phase":"","brief_title":"Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy","source_id_and_acronym":"NCT07122466","lead_sponsor":"Northwell Health","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 10/17/2023","primary_completion_date":" 10/17/2023","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-08-14"},{"id":"b5fd76f4-90b4-4b35-893f-158f34042775","acronym":"MATTERS","url":"https://clinicaltrials.gov/study/NCT04467593","created_at":"2025-08-09T14:50:03.958Z","updated_at":"2025-08-09T14:50:03.958Z","phase":"","brief_title":"Safety Study of Whole Body Hyperthermia for Advanced Cancer","source_id_and_acronym":"NCT04467593 - MATTERS","lead_sponsor":"ElmediX","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 07/28/2021","start_date":" 07/28/2021","primary_txt":" Primary completion: 12/25/2024","primary_completion_date":" 12/25/2024","study_txt":" Completion: 12/25/2024","study_completion_date":" 12/25/2024","last_update_posted":"2025-08-05"},{"id":"62872999-7328-472a-bcf9-8d2b97b69282","acronym":"","url":"https://clinicaltrials.gov/study/NCT07053202","created_at":"2025-07-12T13:55:24.826Z","updated_at":"2025-07-12T13:55:24.826Z","phase":"","brief_title":"TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma","source_id_and_acronym":"NCT07053202","lead_sponsor":"The First Hospital of Hebei Medical University","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-07-08"},{"id":"955c5465-ea4e-4842-8504-e6f530022df5","acronym":"","url":"https://clinicaltrials.gov/study/NCT07043270","created_at":"2025-07-05T13:59:36.534Z","updated_at":"2025-07-05T13:59:36.534Z","phase":"Phase 2","brief_title":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","source_id_and_acronym":"NCT07043270","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2025-07-02"},{"id":"117ac5eb-6cd3-4e16-a1da-430f5c6a5c3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT07045571","created_at":"2025-07-05T14:02:04.651Z","updated_at":"2025-07-05T14:02:04.651Z","phase":"","brief_title":"MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer","source_id_and_acronym":"NCT07045571","lead_sponsor":"Yingbin Liu, MD, PhD, FACS","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 10/30/2022","start_date":" 10/30/2022","primary_txt":" Primary completion: 01/22/2026","primary_completion_date":" 01/22/2026","study_txt":" Completion: 07/22/2026","study_completion_date":" 07/22/2026","last_update_posted":"2025-07-01"},{"id":"b7d6e6ed-0f9e-4f9a-bf98-0d5c3c7402f8","acronym":"IPMN-GLP1RA","url":"https://clinicaltrials.gov/study/NCT07014709","created_at":"2025-06-14T13:55:08.029Z","updated_at":"2025-06-14T13:55:08.029Z","phase":"","brief_title":"Impact of GLP-1 Receptor Agonists on Patients With IPMN","source_id_and_acronym":"NCT07014709 - IPMN-GLP1RA","lead_sponsor":"Hôpital Fribourgeois","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/31/2025","start_date":" 05/31/2025","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2025-06-11"},{"id":"ba38e7d6-cf30-459e-86ad-9dab62c47dd9","acronym":"FIRE-11","url":"https://clinicaltrials.gov/study/NCT07004413","created_at":"2025-06-07T14:43:38.689Z","updated_at":"2025-06-07T14:43:38.689Z","phase":"Phase 3","brief_title":"Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients","source_id_and_acronym":"NCT07004413 - FIRE-11","lead_sponsor":"Charite University, Berlin, Germany","biomarkers":" BRAF • CA 19-9","pipe":"","alterations":" ","tags":["BRAF • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 267","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2025-06-04"},{"id":"7aa880e7-6b68-409d-ae45-4371e34c60af","acronym":"","url":"https://clinicaltrials.gov/study/NCT06979895","created_at":"2025-06-28T16:15:27.825Z","updated_at":"2025-06-28T16:15:27.825Z","phase":"","brief_title":"Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer","source_id_and_acronym":"NCT06979895","lead_sponsor":"Xijing Hospital","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/25/2025","start_date":" 05/25/2025","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-05-20"},{"id":"7fb758c7-b8fb-4644-98e6-5e5ff6f4a102","acronym":"","url":"https://clinicaltrials.gov/study/NCT06979882","created_at":"2025-06-28T16:15:27.370Z","updated_at":"2025-06-28T16:15:27.370Z","phase":"","brief_title":"Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Intestinal Carcinoma","source_id_and_acronym":"NCT06979882","lead_sponsor":"Xijing Hospital","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 05/25/2025","start_date":" 05/25/2025","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-05-20"},{"id":"dfadf95a-f23a-4a0a-9690-cd05cb17f698","acronym":"","url":"https://clinicaltrials.gov/study/NCT06979869","created_at":"2025-06-28T16:15:26.907Z","updated_at":"2025-06-28T16:15:26.907Z","phase":"","brief_title":"Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Esophageal Carcinoma","source_id_and_acronym":"NCT06979869","lead_sponsor":"Xijing Hospital","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 05/25/2025","start_date":" 05/25/2025","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-05-20"},{"id":"5e80e055-53fb-476a-823d-dd55cbbde48c","acronym":"CLARITI","url":"https://clinicaltrials.gov/study/NCT06947382","created_at":"2025-09-07T01:25:10.607Z","updated_at":"2025-09-07T01:25:10.607Z","phase":"","brief_title":"Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer","source_id_and_acronym":"NCT06947382 - CLARITI","lead_sponsor":"Immunovia, Inc.","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Completed","enrollment":" Enrollment 1066","initiation":"Initiation: 09/02/2024","start_date":" 09/02/2024","primary_txt":" Primary completion: 12/09/2024","primary_completion_date":" 12/09/2024","study_txt":" Completion: 01/06/2025","study_completion_date":" 01/06/2025","last_update_posted":"2025-04-27"},{"id":"9a5ed2f1-0ba5-4ea5-9318-4cb37ecaf26a","acronym":"VERIFI","url":"https://clinicaltrials.gov/study/NCT06947395","created_at":"2025-07-19T13:21:57.123Z","updated_at":"2025-07-19T13:21:57.123Z","phase":"","brief_title":"Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)","source_id_and_acronym":"NCT06947395 - VERIFI","lead_sponsor":"Immunovia, Inc.","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Completed","enrollment":" Enrollment 386","initiation":"Initiation: 02/11/2025","start_date":" 02/11/2025","primary_txt":" Primary completion: 03/24/2025","primary_completion_date":" 03/24/2025","study_txt":" Completion: 04/07/2025","study_completion_date":" 04/07/2025","last_update_posted":"2025-04-27"},{"id":"f73e8116-9f3f-4e3c-8faf-7a232f425d23","acronym":"","url":"https://clinicaltrials.gov/study/NCT03861702","created_at":"2025-09-13T13:10:53.052Z","updated_at":"2025-09-13T13:10:53.052Z","phase":"Phase 2","brief_title":"Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:","source_id_and_acronym":"NCT03861702","lead_sponsor":"Nelson Yee","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 08/16/2023","primary_completion_date":" 08/16/2023","study_txt":" Completion: 09/27/2024","study_completion_date":" 09/27/2024","last_update_posted":"2025-04-18"},{"id":"3ed2719e-561e-41cf-943c-89926f1e9bc8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05306028","created_at":"2023-12-15T20:17:43.728Z","updated_at":"2025-02-25T13:40:56.951Z","phase":"Phase 2","brief_title":"Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)","source_id_and_acronym":"NCT05306028","lead_sponsor":"Fudan University","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"9366e737-3f01-4636-8df7-72a9b9c74478","acronym":"CF102-222PC","url":"https://clinicaltrials.gov/study/NCT06387342","created_at":"2024-04-29T15:45:20.577Z","updated_at":"2025-02-25T12:39:00.064Z","phase":"Phase 2","brief_title":"Namodenoson Treatment of Advanced Pancreatic Cancer","source_id_and_acronym":"NCT06387342 - CF102-222PC","lead_sponsor":"Can-Fite BioPharma","biomarkers":" CEACAM5 • CA 19-9","pipe":"","alterations":" ","tags":["CEACAM5 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e namodenoson (CF102)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/10/2024","start_date":" 11/10/2024","primary_txt":" Primary completion: 07/15/2026","primary_completion_date":" 07/15/2026","study_txt":" Completion: 12/15/2026","study_completion_date":" 12/15/2026","last_update_posted":"2025-01-31"},{"id":"a575da2d-72a1-4264-aaeb-fbc4aebb6b41","acronym":"","url":"https://clinicaltrials.gov/study/NCT06766019","created_at":"2025-02-26T07:14:21.939Z","updated_at":"2025-02-26T07:14:21.939Z","phase":"Phase 2","brief_title":"Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer","source_id_and_acronym":"NCT06766019","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • AiRuiLi (adebrelimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 10/16/2024","start_date":" 10/16/2024","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-01-09"},{"id":"7cb5a5f1-41de-427f-b3fb-2b1df2ca90bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06665334","created_at":"2025-02-26T15:16:53.896Z","updated_at":"2025-02-26T15:16:53.896Z","phase":"Phase 4","brief_title":"To Explore the Effect of Huaier Granule on the Negative Conversion Rate After the CEA Level Increases Again After Colorectal Cancer Surgery","source_id_and_acronym":"NCT06665334","lead_sponsor":"Fudan University","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 134","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-10-31"},{"id":"88bf7c40-1a30-459a-8693-a4d5d65c020b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06587061","created_at":"2025-02-26T14:52:08.919Z","updated_at":"2025-02-26T14:52:08.919Z","phase":"Phase 2","brief_title":"HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","source_id_and_acronym":"NCT06587061","lead_sponsor":"Ruijin Hospital","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • HRS-4642"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-09-19"},{"id":"a8d57ddd-693b-4bcf-9406-6ea1ae875f39","acronym":"","url":"https://clinicaltrials.gov/study/NCT06531902","created_at":"2025-02-27T07:58:29.598Z","updated_at":"2025-02-27T07:58:29.598Z","phase":"","brief_title":"LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC","source_id_and_acronym":"NCT06531902","lead_sponsor":"Ain Shams University","biomarkers":" MIR485 • CA 19-9 • HSP90AA1","pipe":"","alterations":" ","tags":["MIR485 • CA 19-9 • HSP90AA1"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2024-08-01"},{"id":"2cf8d2f9-b993-47bd-a559-97faeff002a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06515587","created_at":"2025-02-27T07:52:04.123Z","updated_at":"2025-02-27T07:52:04.123Z","phase":"","brief_title":"Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT06515587","lead_sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2024-07-23"},{"id":"a0cf279a-8d5c-46c3-9bca-6f57de2820c1","acronym":"NAUTICALCRC","url":"https://clinicaltrials.gov/study/NCT05004350","created_at":"2021-08-13T12:53:27.664Z","updated_at":"2025-02-25T16:16:36.860Z","phase":"Phase 2","brief_title":"A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.","source_id_and_acronym":"NCT05004350 - NAUTICALCRC","lead_sponsor":"Pierre Fabre Medicament","biomarkers":" BRAF • MSI • CEACAM5 • RAF1 • RAS • CA 19-9","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • RAS mutation • RAS wild-type","tags":["BRAF • MSI • CEACAM5 • RAF1 • RAS • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 12/19/2023","primary_completion_date":" 12/19/2023","study_txt":" Completion: 01/11/2025","study_completion_date":" 01/11/2025","last_update_posted":"2024-06-18"},{"id":"48b656e8-4c22-468c-bc06-245ca641e6e5","acronym":"NeoOPTIMIZE","url":"https://clinicaltrials.gov/study/NCT04539808","created_at":"2023-11-15T16:14:43.208Z","updated_at":"2024-07-02T16:35:09.940Z","phase":"Phase 2","brief_title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","source_id_and_acronym":"NCT04539808 - NeoOPTIMIZE","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/27/2021","start_date":" 05/27/2021","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 10/05/2025","study_completion_date":" 10/05/2025","last_update_posted":"2024-04-12"},{"id":"b3d1f112-0e04-4d4b-9834-315e4294e693","acronym":"","url":"https://clinicaltrials.gov/study/NCT04674956","created_at":"2024-04-02T20:40:59.614Z","updated_at":"2024-07-02T16:35:11.876Z","phase":"Phase 3","brief_title":"A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT04674956","lead_sponsor":"RenJi Hospital","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • AiRuiKa (camrelizumab) • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 401","initiation":"Initiation: 03/04/2021","start_date":" 03/04/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-04-02"}]